Dual targeted therapy with anakinra and Janus kinase inhibition in multidrug-refractory adult-onset still’s disease: a case report with nearly 7 years of follow-up

Adult-onset Still's disease (AOSD) refractory to standard therapies remains a therapeutic challenge. Interleukin-1 signalling is independent of the Janus kinase (JAK) pathway, providing a rationale for combining anakinra with a JAK inhibitor (JAKi), although long-term clinical data are scarce. We describe a man diagnosed with AOSD at 28 years of age who presented with spiking fever, atypical flagellate rash, sore throat, polyarthritis, hepatosplenomegaly, serositis, neutrophilic leucocytosis, liver enzyme abnormalities, and a peak serum ferritin of 48,288 µg/L (glycosylated ferritin fraction ≤18%), fulfilling both Yamaguchi and Fautrel classification criteria. He also developed life-threatening myopericarditis with cardiac tamponade. Systemic manifestations responded to glucocorticoids and anakinra, but chronic polyarthritis developed that remained refractory over 18 months to anakinra, tocilizumab, etanercept, sarilumab, tofacitinib, and conventional immunosuppressants, with dependence on prednisone 15-20 mg/d. In September 2019, baricitinib was combined with anakinra, achieving low articular disease activity within weeks and allowing prednisone to be tapered to 5 mg/d. After secondary loss of articular response in May 2025, baricitinib was replaced by filgotinib while anakinra was maintained. At the last follow-up in August 2026, systemic manifestations remained controlled, with low articular disease activity and no serious or opportunistic infections, malignancy, venous thromboembolism, or major cardiovascular events during combination therapy. This case documents nearly 7 years of disease control and glucocorticoid sparing with dual targeted JAKi-anakinra therapy in multidrug-refractory AOSD, despite occasional articular flares and previous JAKi failure.

Authors

Institutions

Publication Details

Journal
EULAR Rheumatology Open
Published
2026-11-18
DOI
https://doi.org/10.1016/j.ero.2026.100278
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dual targeted therapy with anakinra and Janus kinase inhibition in multidrug-refractory adult-onset still’s disease: a case report with nearly 7 years of follow-up

Judith Palacios-Olid, Javier Narváez
1 links
EULAR Rheumatology Open
Autoimmune and Inflammatory Disorders Research
article

Dual targeted therapy with anakinra and Janus kinase inhibition in multidrug-refractory adult-onset still’s disease: a case report with nearly 7 years of follow-up

Judith Palacios-Olid, Javier Narváez
article en

Abstract

Adult-onset Still's disease (AOSD) refractory to standard therapies remains a therapeutic challenge. Interleukin-1 signalling is independent of the Janus kinase (JAK) pathway, providing a rationale for combining anakinra with a JAK inhibitor (JAKi), although long-term clinical data are scarce. We describe a man diagnosed with AOSD at 28 years of age who presented with spiking fever, atypical flagellate rash, sore throat, polyarthritis, hepatosplenomegaly, serositis, neutrophilic leucocytosis, liver enzyme abnormalities, and a peak serum ferritin of 48,288 µg/L (glycosylated ferritin fraction ≤18%), fulfilling both Yamaguchi and Fautrel classification criteria. He also developed life-threatening myopericarditis with cardiac tamponade. Systemic manifestations responded to glucocorticoids and anakinra, but chronic polyarthritis developed that remained refractory over 18 months to anakinra, tocilizumab, etanercept, sarilumab, tofacitinib, and conventional immunosuppressants, with dependence on prednisone 15-20 mg/d. In September 2019, baricitinib was combined with anakinra, achieving low articular disease activity within weeks and allowing prednisone to be tapered to 5 mg/d. After secondary loss of articular response in May 2025, baricitinib was replaced by filgotinib while anakinra was maintained. At the last follow-up in August 2026, systemic manifestations remained controlled, with low articular disease activity and no serious or opportunistic infections, malignancy, venous thromboembolism, or major cardiovascular events during combination therapy. This case documents nearly 7 years of disease control and glucocorticoid sparing with dual targeted JAKi-anakinra therapy in multidrug-refractory AOSD, despite occasional articular flares and previous JAKi failure.

EULAR Rheumatology OpenVol. 2(4)
Bellvitge University Hospital (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Universitat de Barcelona (ES)
Good health and well-being
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon